Market Overview

Enzo Biochem Announces NYS Department of Health's Approval of a New Women's Health Infectious Disease Panel


Provides the Ability to Diagnose up to 13 Different Female Infections
from a Single Swab Sample Combined with Enzo's Other Approved Panels

Furthers Enzo's Development Program of Robust, Medically Relevant &
Affordable Molecular Diagnostic Products and Services Addressing the
Clinical Lab Industry's Financial Pressures

Enzo Biochem Inc. (NYSE:ENZ) today announced it has received approval of
another women's health infectious disease diagnostic panel, which when
combined with the Company's previously approved panels, makes for one of
the most comprehensive, efficient and affordable diagnostic products and
services on the market today. A variety of infections, including
sexually transmitted ones, are detected from a single vaginal swab
collection via the Company's proprietary, versatile and cost-effective
AMPIPROBE® platform. The announcement results from recent
action by the New York State Department of Health granting conditional
approval of the new panel's 5 additional tests, complementing the
already approved 8 infectious disease tests for a total of 13 organisms
being detectable from a single vaginal swab specimen.

Enzo's expanding women's infectious disease menu complements and
continues Enzo's decades long offering of women's health tests including
a focused cancer offering. In the early 1980s, Enzo brought the first in
situ HPV cervical cancer detection system to the marketplace. Enzo's
offerings have grown to include immunohistochemistry and gene expression
platforms for detecting women's cancers. The latest infectious disease
panel follows previously approved AmpiProbe® real time
amplification detection tests for qualitative detection of diseases such
as Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis
and Candida spp (C. albicans, C. glabrata, C. krusei, C. parapsilosis,
C. tropicalis). The newly approved tests for bacterial vaginosis (BV),
including Atopobium vaginae, Gardnerella vaginalis, Lactobacillus spp,
Megasphera spp and BVAB2, will now make Enzo's women's health panel one
of the most comprehensive on the market.

Because of the panel's comprehensiveness and high sensitivity, it
quickly and conveniently provides doctors and patients with a result.
Where previously a patient may have had to visit her physician multiple
times for multiple tests before a diagnosis was reached, causing
inconvenience and expense, this panel should reduce those challenges.

Elazar Rabbani, PhD, Enzo Chairman and CEO said, "This underscores that
our extensive product and services pipeline is moving along on schedule.
We remain intently focused on developing and offering highly effective
and affordable diagnostic products and services as solutions to the
increasing financial pressures on the clinical laboratory industry from
both diminishing reimbursements and the high cost of goods, particularly
in the molecular diagnostic arena."

Dr. Rabbani added that, "Since Enzo's inception, we have been committed
to advancing healthcare, and providing affordable and reliable
diagnostic testing. Enzo is uniquely able to target its integrated
diagnostic products and services corporate structure which allows our
Company to create cost-effective solutions for the diagnostics market by
a process involving technology development, manufacturing, clinical
validation and commercialization, while also providing advanced
state-of-the-art diagnostic laboratory and reference services. The
Company will continue to offer products and services to the clinical
laboratory industry at discounts from prevailing market prices."

Enzo's development program includes a line of assays based on its
proprietary labelling and detection technologies for different
applications such as cancer, infectious disease and immunology. The
announcement today is the result of Enzo's concerted use of its
proprietary AMPIPROBE® platform. The next AmpiProbe®
based pipeline panel under development will address the quantification
of viral load in serum or plasma specimens. With the Company's
AmpiProbe-HCV® assay for the quantitative detection of
Hepatitis C virus already approved, and with the addition of AmpiProbe®
detection of Hepatitis B virus and HIV in development, that panel is
well on the way towards additional assays. The Company is also
developing a line of products designed to aid pathologists in
differentiating the characteristics of various tumors from biopsy
specimens. Also in the Company's pipeline is a line of assays based on
its proprietary flow cytometry platform for diverse applications in
areas such as limitation cancer, immunology and infectious disease.
Moreover, many of the Company's existing molecular diagnostic tests can
be extended, such as, for example, extending the detection of vaginal
HPV in women, to detecting HPV in oral and anal locations in men and
women. Enzo's molecular-based products and services target a domestic
laboratory market currently estimated to be in excess of $3 billion in

Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and intellectual
property through the development of unique diagnostic platform
technologies that provide numerous advantages over previous standards. A
global company, Enzo Biochem utilizes cross-functional teams to develop
and deploy products systems and services that meet the ever-changing and
rapidly growing needs of healthcare today and into the future.
Underpinning Enzo Biochem's products and technologies is a broad and
deep intellectual property portfolio, with patent coverage across a
number of key enabling technologies.

Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management, including those related
to cash flow, gross margins, revenues, and expenses which are dependent
on a number of factors outside of the control of the Company including,
inter alia, the markets for the Company's products and services, costs
of goods and services, other expenses, government regulations,
litigation, and general business conditions. See Risk Factors in the
Company's Form 10-K for the fiscal year ended July 31, 2017. Investors
are cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and
uncertainties that could materially affect actual results. The Company
disclaims any obligations to update any forward-looking statement as a
result of developments occurring after the date of this press release.

View Comments and Join the Discussion!